All updates
All updates
today 44中文产业新闻精选Chinese source评分6161 监管与产业动态精选评分8888 Triple-action drug retatrutide delivers major weight loss for people with diabetes, Phase III trial finds
监管与产业动态精选评分6565 Targeted radioactive therapy may help delay spread of recurrent prostate cancer
监管与产业动态评分5858 BioNTech’s mRNA cancer vaccine fails phase 3 test, significantly denting analysts’ confidence - Fierce Biotech
监管与产业动态评分5858 Drug tapering noninferior to treatment continuation for rheumatoid arthritis with low disease activity
监管与产业动态评分5959 Scientists identify clues to making immunotherapy more effective against glioblastoma
监管与产业动态评分4949 Enhanced CAR T-cell therapy shows early promise for B-cell cancers in first-in-human trial
中文产业新闻Chinese source评分5454 百时美施贵宝能否靠两项 III 期顶线结果填补 2028 年专利悬崖百亿缺口
中文产业新闻Chinese source评分6464 BioNTech BNT113头颈癌2/3期临床未达PFS主要终点
中文产业新闻Chinese source评分3333 Amgen启动maridebart cafraglutide针对2型糖尿病/肥胖/超重的Ⅲ期临床试验
中文产业新闻Chinese source评分3535 瑞博生物沃托司兰针对非瓣膜性房颤患者启动Ⅱ期临床试验
中文产业新闻Chinese source评分5858 BMS 公布 Admilparant 与 RYZ101 两项 III 期试验成功
中文产业新闻Chinese source评分1717 BMS 两项 III 期临床成功却致股价下跌
中文产业新闻Chinese source评分7171 信达生物 IBI311 三期 RESTORE-3 达主要终点，突眼应答率 60.4%
中文产业新闻Chinese source评分5959 axatilimab 特发性肺纤维化二期试验未达主要终点
中文产业新闻Chinese source评分5050 axatilimab 治疗 IPF 的 MAXPIRe II 期未达主要终点，Syndax 股价盘后大跌近 17%
中文产业新闻精选Chinese source评分8989 康方依沃西一线晚期肺癌头对头 K 药 总生存期 30.8 个月对 22.6 个月
中文产业新闻精选Chinese source评分7272 BioNTech BNT113联合帕博利珠单抗AHEAD-MERIT 2/3期首批顶线未达PFS主要终点
中文产业新闻Chinese source评分6868 BioNTech BNT113 mRNA肿瘤疫苗AHEAD-MERIT研究未达PFS主要终点
临床试验登记评分2222 A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001)
临床试验登记评分3434 A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children
临床试验登记评分2525 Ofatumumab in Treatment-Refractory¬ Narcolepsy Type 1
临床试验登记评分3232 Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)
临床试验登记评分3535 Vortosiran in Atrial Fibrillation
临床试验登记评分2424 ELITE: Deep Profiling and Algorithmic Polytherapy to Map Individual Response in Healthy Aging
临床试验登记评分3232 Lenvatinib Plus Bevacizumab and PD-1 Inhibition Versus Bevacizumab Plus PD-1 Inhibition After Progression on Bevacizumab Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Prospective, Randomized, Two-Cohort, Phase II Study
临床试验登记评分2929 Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight
临床试验登记评分1818 ITR-251 in Patients With Advanced Solid Tumors
临床试验登记评分2929 Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART)
临床试验登记评分3535 BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy
临床试验登记评分3030 Effects of Switch to Doravirine/Islatravir vs. Continued Antiretroviral Therapy on Biomarkers of Aging Among Virologically Suppressed People With HIV
BioPharma Dive评分6868 BioNTech mRNA cancer immunotherapy misses first objective in key study
中文产业新闻Chinese source评分6262 BioNTech BNT113 联合帕博利珠单抗头颈癌 2/3 期试验未达 PFS 主要终点
中文产业新闻Chinese source评分6161 BMS LPA1 拮抗剂 IPF 三期：60mg 达主要终点，120mg 未达标
JAMA评分4646 Cold and Room-Temperature Platelets in Cardiac Surgery Research Summary
JAMA精选评分6767 Cold and Room-Temperature Platelets in Cardiac Surgery
JAMA评分2525 Daily Zinc Supplementation for Infection Prevention in Children With Sickle Cell Anemia Research Summary
JAMA评分3131 Arginine Therapy for Sickle Cell Disease Acute Pain Episodes Research Summary
JAMA评分4242 Daily Zinc Supplementation for Infection Prevention in Children With Sickle Cell Anemia
JAMA评分4141 Arginine Therapy for Sickle Cell Disease Acute Pain Episodes